Mechano Growth Factor E-Peptide
Evidence: CGH Axis / Body Composition
Evidence Snapshot
What this grade covers
C is the single overall page grade. Confidence in the underlying transcript/splice-variant identity biology (what IGF-1Ec is and how the synthetic MGF E-peptide relates to it) is stronger than the grade for treatment evidence, but that identity-level confidence does not upgrade therapeutic-efficacy grading. Preclinical synthetic-peptide administration evidence is moderate-to-weak and internally mixed, including a negative finding (PMID 24253050, no apparent effect on myoblasts or primary muscle stem cells). Human therapeutic efficacy, approval, safety, or muscle-repair evidence remains very weak to absent.
Regulatory Context
No FDA-approved MGF medicine identified; MGFs are prohibited in sport under WADA rules.
Research Takeaway
IGF-1Ec is an alternatively spliced IGF-1 transcript/propeptide context associated with mechanically responsive tissues; synthetic MGF E-peptide is an isolated experimental peptide derived from IGF-1Ec's unique E-domain. The two are biologically related but are not the same chemical entity, and endogenous IGF-1Ec expression studies are not synthetic-MGF treatment studies. Synthetic MGF E-peptide remains distinct from mature IGF-1 and from PEG-MGF.
Evidence boundary: Endogenous splice-variant expression must not be conflated with pharmacology of a commercial synthetic peptide.
See all 7 evidence claims →Quick Summary
Mechano Growth Factor E-peptide (MGF E-peptide, commonly shortened to "MGF") is a synthetic peptide corresponding to the E-domain of IGF-1Ec, the mechanically responsive splice-isoform/propeptide transcript of IGF-1. IGF-1Ec is the parent splice-isoform context this synthetic peptide is derived from -- not an alternate name for the same molecule -- and endogenous IGF-1Ec expression studies (measuring gene expression after exercise or mechanical loading) are evidence about the body's own transcript biology, not about administering the synthetic E-peptide. Direct synthetic-MGF-E-peptide cell/animal studies exist separately and may support exact-compound mechanistic/preclinical claims, but no adequate human therapeutic trial establishes synthetic MGF for muscle gain, recovery, anti-aging, or injury repair. PEG-MGF is a separate PEGylated entity and is not evidence for unmodified MGF E-peptide, or vice versa.
Mechanism & Research Overview
Mechanical loading can alter IGF-1 splice-variant expression in muscle. However, full-length IGF-1Ec/MGF, endogenous mRNA expression, and synthetic short E-domain peptides are distinct research entities. Receptor and cell studies show that results depend heavily on which molecular form was tested.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
IGF-1Ec is an alternatively spliced IGF-1 transcript/propeptide context associated with mechanically responsive tissues; synthetic MGF E-peptide is an isolated experimental peptide derived from IGF-1Ec's unique E-domain. The two are biologically related but are not the same chemical entity, and endogenous IGF-1Ec expression studies are not synthetic-MGF treatment studies. Synthetic MGF E-peptide remains distinct from mature IGF-1 and from PEG-MGF.
Does not establish
Evidence boundary: Endogenous splice-variant expression must not be conflated with pharmacology of a commercial synthetic peptide.
Sources: Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro; Insulin-like growth factor I (IGF-1) Ec/Mechano Growth factor--a splice variant of IGF-1 within the growth plate
Supported
Human exercise studies show transient regulation of endogenous MGF/IGF-1Ec expression after resistance exercise or muscle damage.
Does not establish
Evidence boundary: Endogenous expression after exercise does not establish benefit from administering synthetic MGF.
Supported
No FDA-approved drug product named Mechano Growth Factor was identified in the Drugs@FDA search performed for this frozen package.
Does not establish
Evidence boundary: This does not address endogenous IGF-1 biology or differently named approved IGF products.
Supported
Published mechanistic studies are not uniformly positive: one study found no apparent effect of the tested MGF peptide on myoblasts or primary muscle stem cells.
Does not establish
Evidence boundary: A negative cell result does not establish toxicity; it demonstrates uncertainty in the claimed mechanism.
Supported
No controlled human administration trial in this frozen package establishes synthetic MGF as an effective muscle-growth or injury-recovery treatment.
Does not establish
Evidence boundary: Human endogenous-expression data cannot be marketed as human treatment efficacy.
Supported
Only experimental exposures from named studies may appear and must be labeled by model; no human consumer dosing or conversion from cell or animal experiments is permitted.
Does not establish
Evidence boundary: Research concentrations are not treatment recommendations.
Supported
MGF E-peptide (synthetic Mechano Growth Factor E-domain peptide) is the compound this page is about; IGF-1Ec is the parent splice-isoform/propeptide transcript context it is derived from, not an alternate name for the same molecule. IGF-1Ec and IGF-IEc were previously listed as chemical-identity aliases of this record and have been removed from that list to avoid implying they are the identical substance as the synthetic E-peptide.
Does not establish
Evidence boundary: This distinction does not change any prior finding about synthetic MGF E-peptide's own preclinical evidence -- it only separates transcript/endogenous evidence from synthetic-peptide evidence at the identity/alias level.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Studies of endogenous IGF-1Ec expression, full-length MGF, and short synthetic E-peptides are often incorrectly combined.Safety Consideration
Human studies located measured endogenous expression rather than dosing a synthetic MGF product.Safety Consideration
Some cell experiments reported proliferative effects while another found no apparent effect on myoblasts or primary muscle stem cells.Safety Consideration
Full-length MGF can activate IGF-1 and insulin receptors in vitro at high concentrations; human implications are unknown.Safety Consideration
Products sold as MGF may not match the molecular form used in cited experiments and may carry purity or labeling risks.Safety Consideration
Important concerns include angiogenesis and tumor risk, off-target tissue growth, cardiac, retinal, neurologic, reproductive, and developmental effects, interaction with GH, IGF-I analogues, insulin, anabolic steroids, or cancer therapy, hypoglycemia and metabolic effects, proliferative and anti-apoptotic signaling, and unknown chronic and repeated-dose safety. Identity ambiguity, misfolding, aggregation, impurities, immunogenicity, and sterility/endotoxin risk compound these uncertainties for marketplace products.
Research Areas Being Studied
Research areas discussed on this page reflect the GH Axis / Body Composition category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro (2009):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro | 2009 | After exercise-induced muscle damage, MGF/IGF-1Ec expression changed in human skeletal muscle; synthetic MGF E-peptide showed proliferative effects in vitro distinct from mature IGF-1 signaling. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Insulin-like growth factor I (IGF-1) Ec/Mechano Growth factor--a splice variant of IGF-1 within the growth plate | 2013 | The paper describes IGF-1Ec/MGF as an IGF-1 splice variant and a 24-amino-acid human E-peptide concept, while finding no proliferation of growth-plate chondrocytes after MGF peptide exposure. | |||
| Producing Human Mechano Growth Factor in Escherichia coli | Describes laboratory expression of full-length recombinant human MGF/pro-IGF-1Ec in E. coli. Full-length recombinant-protein evidence cannot be assigned to the 24-amino-acid synthetic E-domain peptide or to marketplace products of uncertain sequence and purity. | ||||
| Synthetic MGF E-Domain Peptide (MGF-Ct24E) and Human Myogenic Precursor Cell Migration | A synthetic MGF-Ct24E E-domain peptide promoted migration of human myogenic precursor cells in cell-based assays. This is a cell finding and does not establish human muscle hypertrophy, injury recovery, or disease treatment; independent replication attempts with MGF peptides found no apparent effect under different conditions. | ||||
| Synthetic MGF E-Peptide and Human Myogenic Precursor Cell Transplantation in Mice | Synthetic MGF E-peptide co-treatment improved engraftment of transplanted human myogenic precursor cells in a mouse model. This is a cell/animal transplantation finding, not a human treatment trial, and does not establish muscle repair or safety in humans. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Drugs@FDA: FDA-Approved Drugs Database | 2026 | Current Drugs@FDA name searches performed for this frozen package did not identify approved drug products under the names AHK-Cu, FOXO4-DRI, Pinealon, or Mechano Growth Factor. A negative name search does not exclude differently named products but establishes that no approval was identified under these research names. | |||
| FDA 503A Bulk Drug Substances Categories, Updated May 14, 2026 (Mechano Growth Factor, Category 3) | 2026 | FDA's May 14, 2026 503A bulk drug substance category document places Mechano Growth Factor in Category 3, meaning it was nominated without adequate support. Category 3 is not FDA approval, is not inclusion on the 503A Bulks List, is not Category 1 status, and does not establish compounding eligibility, safety, or effectiveness. | |||
| FDA Safety Risks for Certain Compounded Bulk Drug Substances | FDA describes safety risks associated with certain compounded bulk drug substances, including identity, purity, and quality uncertainty. PEG-MGF has separate FDA safety concerns documented elsewhere and must not be merged into this page's MGF discussion. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Biological Activity of the E Domain of the IGF-1Ec (Mechano Growth Factor) | A review of E-domain/MGF biological activity discusses proposed IGF-I-receptor-independent signaling and tissue-repair roles while noting that an autonomous circulating 24-amino-acid E-domain peptide has not been definitively isolated from human tissues or biological fluids. Transcript-level and full-length-protein evidence cannot be assumed to establish this. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
MGF research involves multiple molecular identities and lacks a verified human administration evidence base. This page is educational only, not medical advice, and not a recommendation.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for Mechano Growth Factor E-Peptide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.